Skip to content

InvestorsNASDAQ: ANIX

Stock SEC Filings

Back to anixa.com

Corporate deck Contact Investor FAQs

Loading…

NASDAQ: ANIXBack to anixa.com

Company

Overview
Leadership
Governance
Contact

Investors

Press Releases
Events & Webcasts
Stock Information
SEC Filings

Resources

Presentations
Email Alerts
Investor FAQs

Anixa Biosciences, Inc. uses its investor relations website as a recognized channel for disclosing material, non-public information and for complying with its disclosure obligations under Regulation FD. Investors should monitor this site, along with the company's press releases, SEC filings, and public conference calls and webcasts.

© 2026 Anixa Biosciences, Inc.Privacy Terms Accessibility

Site by Front Yard and Crescendo Communications

We use cookies to power embedded market data and to remember your alert preferences. You can decline non-essential cookies.

Anixa in the News

Selected coverage, interviews, and features from third-party outlets.

Featured
Promising breast cancer vaccine advances in trials
Fox News · Video · Feb 15, 2025
Misinformation, hesitancy could blunt impact of new cancer vaccines
Stateline · Article · Sep 14, 2026
A Breast Cancer Vaccine Built to Prevent & Treat
ChalkTalkJim: Breaking Down the Game - A Guide to the Future of Healthcare · Podcast · Sep 03, 2026
Meet the Disruptors: Amit Kumar Of Anixa Biosciences On 5 Things You Need To Shake Up Your Industry
Authority Magazine · Article · Aug 27, 2026
mRNA Cancer Vaccine Breakthrough: What Moderna and Merck’s Phase 3 Melanoma Result Really Means
CWON Press · Article · Aug 26, 2026
A Vaccine To Prevent Breast Cancer Recalibrates The Possible
Outsourced Pharma · Article · Jul 08, 2026
Outsourcing Everything Is The Biotech Blueprint
Outsourced Pharma · Article · Jun 15, 2026

Links to third-party coverage are provided for convenience. The company is not responsible for the content of external sites.

Forward-looking statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Anixa Biosciences' clinical trials, product candidates, regulatory plans, and business strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statements except as required by law.